Establishing EDI for a Clinical Trial of a Treatment for Chikungunya
| Autor: | Robert A. Lodder, Cynthia Dickerson, Mark Ensor |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty 030109 nutrition & dietetics National Health and Nutrition Examination Survey business.industry viruses 010401 analytical chemistry virus diseases Tropical disease Disease medicine.disease medicine.disease_cause 01 natural sciences Virus 0104 chemical sciences Clinical trial 03 medical and health sciences Internal medicine Joint pain medicine Chikungunya medicine.symptom business Encephalitis |
| Zdroj: | Lecture Notes in Computer Science ISBN: 9783319937007 ICCS (2) |
| DOI: | 10.1007/978-3-319-93701-4_61 |
| Popis: | Ellagic acid (EA) is a polyphenolic compound with antiviral activity against chikungunya, a rapidly spreading new tropical disease transmitted to humans by mosquitoes and now affecting millions worldwide. The most common symptoms of chikungunya virus infection are fever and joint pain. Other manifestations of infection can include encephalitis and an arthritic joint swelling with pain that may persist for months or years after the initial infection. The disease has recently spread to the U.S.A., with locally-transmitted cases of chikungunya virus reported in Florida. There is no approved vaccine to prevent or medicine to treat chikungunya virus infections. In this study, the Estimated Daily Intake (EDI) of EA from the food supply established using the National Health and Nutrition Examination Survey (NHANES) is used to set a maximum dose of an EA formulation for a high priority clinical trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|